Current concepts in age related macular degeneration

1 October 2008
Volume 09, Issue 4

A review of the modern classifications of AMD and available treatments.


Age-related macular degeneration (ARMD) is the commonest cause of visual impairment leading to blind registration among older adults in the western world. Following recently published trials, ophthalmologists around the world now have the knowledge and the drugs to improve visual outcomes and to provide much-needed hope to patients with wet macular degeneration. Further, many research trials are currently under way with more funding to find an even more suitable and effective treatment modality for macular degeneration.

Sign in to continue

Forgotten password?

Not already a member of The College?

Start enjoying the benefits of College membership today. Take a look at what the College can offer you and view our membership categories and rates.

Related further reading

A message from Colin Davidson, College President.


Seek out cutting-edge clinical content to address new challenges, says Kieran Loft MCOptom.

This edition takes a look at the risk variants and genetic distribution of Age-related macular degeneration as well as topical ivermectin-metronidazole gel therapy for blepharitis caused by Demodex.